MICROWAVE PORATION THERAPY FOR PROSTATE CANCER

描述：（改编自研究者摘要） 总体建议方案是开发临床上可用的非侵入性 微波穿孔仪器，以增加吸收和保留 化疗药物的靶向恶性细胞，从而显着 增强这些药剂的抗癌活性。拟议 仪器由高峰值功率脉冲微波发生器组成， 输出由非侵入性施加器引导至肿瘤部位， 在低平均功率水平下产生高电场的治疗 其不会引起暴露组织的明显温度升高。 在使用20只哥本哈根大鼠的初步试点研究中， 微波脉冲可以大幅增加全身吸收 循环荧光素右旋糖酐（分子量10，000道尔顿） AT2恶性前列腺肿瘤。没有显著的葡聚糖摄取， 健康的细胞被脉冲，这表明一个很大的治疗优势， 可以通过微波脉冲获得。这项初步研究还表明， 肿瘤的缓解可以通过结合微波脉冲和 全身使用紫杉醇。在拟议的第一阶段计划中，微波 仪器和治疗方案将使用哥本哈根大鼠进行优化 与植入的AT2前列腺肿瘤，和仪器的设计， 将考虑用于未来临床试验的治疗方案。 拟定商业应用： 癌症治疗：（1）较小剂量的化疗药物，从而减少全身 毒性(2)单克隆抗体、放射性核和基因的治疗应用 目标细胞膜孔隙率的增加将促进这一过程。 基因疗法不仅可以治疗癌症，还可以治疗从囊性纤维化到 艾滋病

DESCRIPTION: (Adapted from investigator's abstract) The long-term objective of the overall proposal program is to develop clinically-usable non-invasive microwave poration instrumentation to increase the uptake and retention of chemotherapeutic agents by targeted malignant cells thereby significantly enhancing the anti-cancer activity of these agents. The proposed instrumentation consists of high-peak-power pulsed microwave generators whose output is directed by non-invasive applicators to the tumor site under treatment where high electric fields are developed at low average power levels that do not cause appreciable temperature increases in the exposed tissues. During a preliminary pilot study using 20 Copenhagen rats, it was demonstrated that microwave pulsing could sharply increase the uptake of systemically circulating fluorescin Dextran (10,000 daltons molecular weight) by implanted AT2 malignant prostate tumors. There was no significant uptake of Dextran by healthy cells that were pulsed indicating that a large therapeutic advantage can be obtained by microwave pulsing. This preliminary study also indicated that remission of tumors could be obtained by combining microwave pulsing and systemically administered Taxol. During the proposed Phase I program, microwave instrumentation and treatment protocols will be optimized using Copenhagen rats with implanted AT2 prostate tumors, and the design of instrumentation and treatment protocols for future clinical trials will be considered. PROPOSED COMMERCIAL APPLICATION: Cancer treatment: (1) Smaller doses of chemotherapeutic drugs, thus reducing systemic toxicity. (2) The therapeutic use of monoclonal antibodies, radioactive nuclei, and genes would be facilitated by the increased porosity of the targeted cell membranes. Gene therapy not only for cancer, but also for diseases ranging from cystic fibrosis to AIDS.